Health News

LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in mice. That ability was previously demonstrated by the authors in a study involving a mouse two-stage model of chemically-induced skin cancer.

Read more

Filed under: Pharmacy News
Tags: cancer, Pharmacy, skin cancer, Stress, Tumor

Related posts

• Study reports a potential new investigational therapy for skin cancer (0)
  A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients. Read more [tags] Pharmacy News [/tags]
  
  
• Stress may hasten the growth of melanoma tumors (0)
  (Ohio State University) For patients with a particularly aggressive form of skin cancer -- malignant melanoma -- stress, including that which comes from simply hearing that diagnosis, might amplify the progression of their disease. But the same new research that infers this also suggests that the use of commonly prescribed blood pressure medicines might [...]
  
  
• Single dose of Pain Therapeutics’ PTI-188 decreased melanoma tumors: Study (0)
  Pain Therapeutics, Inc. today announced encouraging clinical data with PTI-188, an early-stage drug for metastatic melanoma. Metastatic melanoma is a lethal form of skin cancer in which patients typically have a median survival time of 9 months. Read more [tags] Pharmacy News [/tags]
  
  
• GDC-0449 inhibits the Hedgehog signaling pathway (0)
  The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage. Read more [tags] Pharmacy News [/tags]
  
  
• ZIOPHARM receives European patent allowance for palifosfamide to treat cancer (0)
  ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer. Read more [tags] Pharmacy [...]